Interesting, they should correct that. I did some searching & found more appropriate descriptions. See below.
From OTC Markets:
"ViaDerma, Inc. is a pharmaceutical company committed to bringing new products to the pharmaceutical industry through innovative research and development. The Company manufactures and sells products in fields of medicine ranging from infectious diseases to stem-cell therapy. The Company?s products are normally applied topically using a patent-pending delivery system technology created by Dr. Phillips and Dr. Chris Ayo Otiko. Presently, the products are used within the OTC drug market, i.e. non-prescription. However, the Company believes the delivery system can be used for the prescription medication market as well not only for topical prescription medications but also to turn certain oral medications into topically based medications. In addition to the primary plan of developing and selling new products to the market, the Company is exploring the possibility of licensing the technology to other pharmaceutical companies."
From Reuters:
"ViaDerma, Inc., incorporated on April 6, 2010, is a pharmaceutical company focused on bringing new products to the pharmaceutical industry through research and development. The Company licenses and sells products in fields of medicine ranging from infectious diseases to stem-cell therapy. The Company's products are applied topically using a delivery system technology. The Company's products are used within the over-the-counter (OTC) drug market. In addition to the primary plan of developing and selling new products to the market, the Company is exploring the possibility of licensing the technology to other pharmaceutical companies. The Company has products in development in various fields, including topical antibiotics (TetraStem), topical anti-viral product (Viralcur) for genital herpes, anti-fungal products for onychomycocis (OnyPro), hair loss prevention product (HairGain), skin cancer therapies (Cantrile), and a topical stem cell therapy product (TetraStem Plus). Its products have a delivery system technology that allows for mass transfer of the pharmaceutical active ingredient across the skin and into the body to provide localized therapy.
The Company has used its dual-carrier technology to develop various products, including ACNECLIR/ACNEEN, which is a salicylic acid-based lotion that treats acne; ACNECYCLINE, which is a tetracycline hydrochloride ointment that treats acne; ADVANCED JELLYFISH STING KIT, which is a zinc acetate powder, for suspension, that treats Jellyfish stings; DERMONEEN, which is a salicylic acid lotion used to treat Psoriasis; ECODERM, which is a colloidal oatmeal lotion for Eczema; IVYMED, which is a zinc acetate-based liquid that treats Poison Ivy rashes; STAPHWASH PLUS, which is a zinc acetate-based non-antibiotic skin cleanser that kills Methicillin-resistant Staphylococcus aureus (MRSA); STINGMED, which is a zinc acetate-based liquid that treats most insect and spider bites; TETRA-ABC, which is a tetracycline hydrochloride-based ointment that kills all known bacterial infections; TETRA-STEM, which is a tetracycline hydrochloride ointment that kills bacteria, including flesh-eating bacteria and can be used to treat wounds, ulcers and burns, and VENOMX, which is a zinc acetate-based liquid used topically to treat snake bites. The Company sells its products to local medical practitioners, primarily in the Los Angeles, California area."
From Market Watch & CNN Money:
"ViaDerma, Inc. is engaged in the manufacturing and sales of pharmaceutical related products. The company was founded on January 1, 2007 and is headquartered in Beverly Hills, CA."
From MorningStar:
"ViaDerma Inc is a specialty pharmaceutical company. The Company through its subsidiary is engaged in the manufacture and sales of specialty pharmaceutical related products in the United States of America."
News 
Market Data 
Discover 
